Direct effects of statins on the vascular wall

被引:84
作者
Corsini, A
Pazzucconi, F
Arnaboldi, L
Pfister, P
Fumagalli, R
Paoletti, R
Sirtori, CR
机构
[1] Univ Milan, Inst Pharmacol Sci, I-20133 Milan, Italy
[2] Univ Milan, Enrica Grossi Paoletti Ctr, Milan, Italy
[3] Novartis Pharma AG, Basel, Switzerland
关键词
myocyte proliferation; cholesterol synthesis; HMG-CoA reductase inhibitors; fluvastatin; pravastatin;
D O I
10.1097/00005344-199805000-00017
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The beneficial effects of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) on coronary events have generally been attributed to their hypocholesterolemic properties. Mevalonate and other intermediates of cholesterol synthesis (isoprenoids) are necessary for cell proliferation and other important cell functions; thus effects other than cholesterol reduction may help to explain the antiatherosclerotic properties of statins. Recently we provided in vitro and in vivo evidence of decreased smooth-muscle cell (SMC) proliferation and migration by fluvastatin and simvastatin, but not by pravastatin, independent of plasma cholesterol reduction. The ability of fluvastatin to interfere with arterial SMC proliferation at therapeutic concentrations (0.1-1 mu M) prompted us to investigate the pharmacologic activity of sera from 10 patients treated with fluvastatin, 40 mg once daily, on the proliferation of cultured human arterial myocytes. Pravastatin, 40 mg once daily, displays a lipid-lowering activity similar to that of fluvastatin without affecting SMC proliferation and was investigated as a control for assessing this non-lipid-related effect of fluvastatin. Fluvastatin and pravastatin, given for 6 days to patients with type IIa hypercholesterolemia, resulted in a similar decrease in low-density-lipoprotein (LDL) cholesterol. However, the addition of 15% whole-blood sera from patients treated with fluvastatin to the culture medium resulted in a 43% inhibition of cholesterol synthesis in SMCs (p < 0.01) that mirrored the pharmacokinetic profile of fluvastatin. When SMC proliferation was investigated, a significant inhibition of cell growth (-30%; p < 0.01) was detected with sera obtained 6 h after the last dose. No effect on SMC proliferation or cholesterol biosynthesis was observed when sera from patients treated with pravastatin were evaluated. These results suggest that statins exert a direct antiproliferative effect on the arterial wall, beyond their effects on plasma lipids, which could prevent significant cardiovascular disease.
引用
收藏
页码:773 / 778
页数:6
相关论文
共 82 条
[1]   MEVINOLIN - A HIGHLY POTENT COMPETITIVE INHIBITOR OF HYDROXYMETHYLGLUTARYL-COENZYME-A REDUCTASE AND A CHOLESTEROL-LOWERING AGENT [J].
ALBERTS, AW ;
CHEN, J ;
KURON, G ;
HUNT, V ;
HUFF, J ;
HOFFMAN, C ;
ROTHROCK, J ;
LOPEZ, M ;
JOSHUA, H ;
HARRIS, E ;
PATCHETT, A ;
MONAGHAN, R ;
CURRIE, S ;
STAPLEY, E ;
ALBERSSCHONBERG, G ;
HENSENS, O ;
HIRSHFIELD, J ;
HOOGSTEEN, K ;
LIESCH, J ;
SPRINGER, J .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA-BIOLOGICAL SCIENCES, 1980, 77 (07) :3957-3961
[2]  
[Anonymous], 1994, CIRCULATION
[3]   LOVASTATIN INHIBITS LOW-DENSITY-LIPOPROTEIN OXIDATION AND ALTERS ITS FLUIDITY AND UPTAKE BY MACROPHAGES - INVITRO AND INVIVO STUDIES [J].
AVIRAM, M ;
DANKNER, G ;
COGAN, U ;
HOCHGRAF, E ;
BROOK, JG .
METABOLISM-CLINICAL AND EXPERIMENTAL, 1992, 41 (03) :229-235
[4]   Inhibitory effect of fluvastatin at doses insufficient to lower serum lipids on the catheter-induced thickening of intima in rabbit femoral artery [J].
Bandoh, T ;
Mitani, H ;
Niihashi, M ;
Kusumi, Y ;
Ishikawa, J ;
Kimura, M ;
Totsuka, T ;
Sakurai, I ;
Hayashi, S .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1996, 315 (01) :37-42
[5]   REQUIREMENT FOR MEVALONATE IN ACETYLATED LDL INDUCTION OF CHOLESTEROL ESTERIFICATION IN MACROPHAGES [J].
BERNINI, F ;
DIDONI, G ;
BONFADINI, G ;
BELLOSTA, S ;
FUMAGALLI, R .
ATHEROSCLEROSIS, 1993, 104 (1-2) :19-26
[6]   HMG-COA REDUCTASE INHIBITORS REDUCE ACETYL LDL ENDOCYTOSIS IN MOUSE PERITONEAL-MACROPHAGES [J].
BERNINI, F ;
SCURATI, N ;
BONFADINI, G ;
FUMAGALLI, E .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1995, 15 (09) :1352-1358
[7]   ANTIATHEROSCLEROTIC ACTIVITY OF INHIBITORS OF 3-HYDROXY-3-METHYLGLUTARYL COENZYME-A REDUCTASE IN CHOLESTEROL-FED RABBITS - A BIOCHEMICAL AND MORPHOLOGICAL EVALUATION [J].
BOCAN, TMA ;
MAZUR, MJ ;
MUELLER, SB ;
BROWN, EQ ;
SLISKOVIC, DR ;
OBRIEN, PM ;
CRESWELL, MW ;
LEE, H ;
UHLENDORF, PD ;
ROTH, BD ;
NEWTON, RS .
ATHEROSCLEROSIS, 1994, 111 (01) :127-142
[8]   LIPID-LOWERING AND PLAQUE REGRESSION - NEW INSIGHTS INTO PREVENTION OF PLAQUE DISRUPTION AND CLINICAL EVENTS IN CORONARY-DISEASE [J].
BROWN, BG ;
ZHAO, XQ ;
SACCO, DE ;
ALBERS, JJ .
CIRCULATION, 1993, 87 (06) :1781-1791
[9]  
BROWN MS, 1991, PHARMACOL BASIS THER, P874
[10]   P21RAS IS MODIFIED BY A FARNESYL ISOPRENOID [J].
CASEY, PJ ;
SOLSKI, PA ;
DER, CJ ;
BUSS, JE .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1989, 86 (21) :8323-8327